Physician profile
Lan Ann Bui
NPI 1255311163
$3,228.98
in general payments reported to CMS, 2019-2025
31 companies · $660 in 2025
The $660 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $217 · 2021: $599 · 2022: $654 · 2023: $372 · 2024: $362 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.48 | 2019-2024 | Orilissa, Lo Loestrin Fe |
| Myovant Sciences INC. | $435.62 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $404.53 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $278.43 | 2019-2025 | Endosee, Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $228.34 | 2019-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima, Thinprep 2000 Processor |
| Aspira Women'S Health INC | $169.83 | 2021 | |
| Mayne Pharma Commercial LLC | $129.80 | 2022-2025 | |
| Astellas Pharma US INC | $123.61 | 2024-2025 | Veozah |
| Organon LLC | $121.31 | 2021-2024 | |
| Channel Medsystems, INC. | $84.44 | 2025 | |
| Pfizer INC. | $64.77 | 2023-2025 | |
| Evofem Biosciences, INC. | $61.06 | 2021-2022 | |
| Daiichi Sankyo INC. | $59.86 | 2019-2022 | |
| Therapeuticsmd, INC. | $52.00 | 2019-2022 | |
| Lupin INC. | $49.47 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $43.39 | 2019-2022 | |
| Sage Therapeutics, LLC | $43.07 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $42.84 | 2021 | |
| Exeltis, USA INC. | $39.95 | 2019-2020 | |
| Abbott Laboratories | $37.24 | 2025 | Alinity M, Freestyle Libre 3 |
| Shield Therapeutics INC | $35.21 | 2022-2024 | |
| Dexcom, INC. | $32.06 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.65 | 2022 | |
| Amag Pharmaceuticals, INC. | $28.40 | 2019-2020 | |
| Allergan, INC. | $27.45 | 2019-2020 | |
| Covidien Lp | $22.69 | 2019 | |
| Exact Sciences Corporation | $18.44 | 2023 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $17.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.93 | 2019 | |
| Baxter Healthcare | $12.95 | 2019 | |
| Duchesnay USA Incorporated | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.